UNSPSC 51152041: Orphenadrine

This classification denotes a muscle relaxant and antimuscarinic agent with the molecular formula C18H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AL805O9OG9, chemically known as n,n-dimethyl-2-(o-methyl-.alpha.-phenylbenzyloxy)ethylamine hydrochloride but generally known as orphenadrine, which bears US NIH Compound Identifier 4601. European Medicines Agency schedules Orphenadrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09471MIG.

UNSPSC 51152041 Orphenadrine, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal scope. The two recent opportunities posted under this code involve naloxone procurement and direct-to-manufacturer pharmacy initiatives, neither of which involves orphenadrine specifically. Seminole County, Florida's IFB60459723LAS solicits 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding for community health initiatives, with quarterly deliveries to the Seminole County Community Health Building and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission's RFI HHS0017013 seeks vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, exploring whether vendors can establish direct relationships with state agencies and self-insured health plans outside traditional pharmacy benefit manager arrangements. Both opportunities involve state health agencies and community health procurement but diverge significantly from the orphenadrine product line itself.

The code shows recent activity only in Florida and Texas, both instances occurring in spring and summer 2026. Orphenadrine as a standalone pharmaceutical procurement does not appear in the recent state and local opportunity record; the misalignment between the code's name and what is actually being solicited under it suggests either miscategorization in the source system or that the code has been repurposed for broader pharmaceutical and pharmacy-related services at the state and local level. Firms pursuing work in this space should monitor whether future solicitations under this code continue to track naloxone, broader pharmacy benefit management services, or other pharmaceutical initiatives rather than orphenadrine specifically.